David A. Siegel Silverback Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 41,000 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,000

Previous 41,400 0.97%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	N/A	-400 Reduced 0.97%	41,000 $0
Q3 2024 Nov 14, 2024	BUY	N/A	17,100 Added 70.37%	41,400 $0
Q2 2024 Aug 14, 2024	BUY	N/A	24,300 New	24,300 $0
Q2 2023 Aug 14, 2023	BUY	N/A	6,000 Added 2.72%	226,800 $0
Q1 2023 May 15, 2023	SELL	N/A	-23,300 Reduced 9.55%	220,800 $0
Q4 2022 Feb 14, 2023	SELL	$0.0 - $6.07 $0 - $155,999	-25,700 Reduced 9.53%	244,100 $0
Q3 2022 Nov 14, 2022	SELL	$3.91 - $5.52 $613,479 - $866,087	-156,900 Reduced 36.77%	269,800 $1.43 Million
Q2 2022 Aug 15, 2022	BUY	$2.9 - $4.44 $162,110 - $248,196	55,900 Added 15.08%	426,700 $1.81 Million
Q1 2022 May 16, 2022	BUY	$3.51 - $6.74 $505,790 - $971,234	144,100 Added 63.56%	370,800 $1.3 Million
Q4 2021 Feb 14, 2022	BUY	$6.03 - $11.67 $1.14 Million - $2.21 Million	189,100 Added 502.93%	226,700 $1.51 Million
Q3 2021 Nov 15, 2021	BUY	$9.98 - $35.22 $375,248 - $1.32 Million	37,600 New	37,600 $375,000

Others Institutions Holding SBTX

# of Institutions

178

Shares Held

70.2M

Call Options Held

218K

Put Options Held

329K

View Full List

About Silverback Therapeutics, Inc.

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

More about SBTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account